Document is current
Any future updates will be listed below
-
Authors
Li, Shuya https://orcid.org/0000-0002-7263-0365
Campbell, Bruce C V
Schwamm, Lee H
Fisher, Marc
Parsons, Mark
Li, Hao https://orcid.org/0000-0002-8591-4105
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Wang, Yongjun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04797013 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design
https://doi.org/10.1136/svn-2021-001074
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial
https://doi.org/10.1136/svn-2024-003726
Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
https://doi.org/10.1136/svn-2023-002694
- License Information
